Molecular imaging with positron emission tomography (PET) using \[18F\] fluorodeoxyglucose (FDG) has been suggested as an early, sensitive marker of tumour response to anticancer drugs by monitoring the changes in glucose metabolism in tumours. Recently, FDG-PET has shown to be highly sensitive in detecting early response in other tumours. In this study, the investigators will prospectively investigate the role of early FDG-PET (at day 7 and week 6) in outcome prediction.
Study Type
OBSERVATIONAL
Enrollment
21
PET-CT
ZNA Middelheim
Antwerp, Belgium
AZ Groeninge
Kortrijk, Belgium
UZLeuven
Leuven, Belgium
H Hart Roeselare Campus menen
Menen, Belgium
Stedelijk Ziekenhuis Roeselare
PET response on day 7
Time frame: day 7
To determine whether the PET criteria for response on day 7 correlates with the CT criteria of minimum 10% decrease in tumour size (RECIST) at week 6
Time frame: week 6
To define the optimal cutoff value of SUVmax and their predictive value
Time frame: at day 7 and week 6
To explore the test/retest reliability of PET/CT in this setting
Time frame: 2 weeks
To assess the value of PET/CT at day 7 in predicting overall survival
Time frame: up to 1 year
To asses the correlations between biomarkers and PET changes after Cetuximab
Time frame: up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Roeselare, Belgium
Sint Augustinus Ziekenhuis
Wilrijk, Belgium